Current clinical perspectives on the treatment of multiple sclerosis

Neurology

Volumn 63, Issue 11 SUPPL. 5, 2004, Pages

  Stuart, William H ^a  

^a Peachtree Neurological Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; NEUTRALIZING ANTIBODY;

ALGORITHM; BIOASSAY; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; DEMYELINATING DISEASE; DISEASE COURSE; EDITORIAL; HUMAN; IMMUNOGENICITY; INFLAMMATION; LONG TERM CARE; MORBIDITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; SPINAL CORD; SYMPTOM;

EID: 10344254817     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.11_suppl_5.s1     Document Type: Editorial

References (8)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231.
2. National Multiple Sclerosis Society. Just the facts: 2003-2004. Available at: http://www.nationalmssodety.org/Brochures-Just%20the.asp. Accessed February 10, 2004.
3. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: quality of life. Can J Neurol Sci 1998;25:31-38.
4. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
5. Jacobs LD, Cookfair DL, Rudick RA, et al, and The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
6. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
7. Johnson KP, Brooks BR, Cohen JA, et al, and the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
8. IMS, 2002.